Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Minority Interest (2022 - 2025)

Historic Minority Interest for Gyre Therapeutics (GYRE) over the last 4 years, with Q3 2025 value amounting to $35.5 million.

  • Gyre Therapeutics' Minority Interest rose 56.67% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year increase of 56.67%. This contributed to the annual value of $35.1 million for FY2024, which is 1781.91% up from last year.
  • Gyre Therapeutics' Minority Interest amounted to $35.5 million in Q3 2025, which was up 56.67% from $37.4 million recorded in Q2 2025.
  • Gyre Therapeutics' Minority Interest's 5-year high stood at $37.4 million during Q2 2025, with a 5-year trough of $29.7 million in Q4 2022.
  • In the last 4 years, Gyre Therapeutics' Minority Interest had a median value of $35.1 million in 2024 and averaged $33.8 million.
  • Per our database at Business Quant, Gyre Therapeutics' Minority Interest increased by 27.61% in 2023 and then skyrocketed by 1781.91% in 2024.
  • Over the past 4 years, Gyre Therapeutics' Minority Interest (Quarter) stood at $29.7 million in 2022, then rose by 0.28% to $29.8 million in 2023, then rose by 17.82% to $35.1 million in 2024, then increased by 1.17% to $35.5 million in 2025.
  • Its last three reported values are $35.5 million in Q3 2025, $37.4 million for Q2 2025, and $36.2 million during Q1 2025.